Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 40Lymphoma 37Lymphoma, Follicular 33Leukemia, Lymphocytic, Chronic, B-Cell 32Lymphoma, Mantle-Cell 23Lymphoma, Non-Hodgkin 22Lymphoma, B-Cell, Marginal Zone 19Burkitt Lymphoma 19Waldenstrom Macroglobulinemia 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 10Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Hairy Cell 6Hodgkin Disease 6Leukemia, Prolymphocytic 5Myelodysplastic Syndromes 4Lymphoma, AIDS-Related 4Dendritic Cell Sarcoma, Interdigitating 4Plasmablastic Lymphoma 3Lymphoma, Primary Effusion 3Lymphoma, Large-Cell, Anaplastic 3HIV Infections 3Epstein-Barr Virus Infections 3Neoplasms, Plasma Cell 2Neoplasms 2Neoplasm, Residual 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Classic Follicular Lymphoma × Rituximab × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡